Enveric Biosciences Buys MagicMed In All Stock Deal Valued At $30 Million

Patient-first biotech company¬†Enveric Biosciences (NASDAQ: ENVB) is buying MagicMed Industries Inc., a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine (DMT) and other molecular derivatives with applications across multiple indications, in an all-stock transaction. The deal has an approximate value of $30 million.¬† Shareholders of MagicMed … Continue reading Enveric Biosciences Buys MagicMed In All Stock Deal Valued At $30 Million